GlassScriptPhysician profile
Harcharan Sandhu
NPI 1790770865
$8,790.75
in general payments reported to CMS, 2019-2025
37 companies · $940 in 2025
The $940 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,738 · 2020: $709 · 2021: $1,081 · 2022: $1,166 · 2023: $1,620 · 2024: $1,536 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.05 |
| Education | $105.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,255.61 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $653.60 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $650.22 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $611.51 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $579.74 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $545.22 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $478.49 | 2019-2022 | |
| Alkermes, INC. | $443.87 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $440.83 | 2019-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $369.82 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $331.03 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $294.07 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $271.17 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $265.77 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $194.28 | 2024-2025 | Cobenfy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $191.01 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $168.03 | 2024 | Auvelity |
| Corium, LLC | $147.87 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $128.24 | 2019-2024 | Jornay Pm |
| Indivior INC. | $115.13 | 2020-2025 | Perseris, Sublocade |
| Bausch Health US, LLC | $99.35 | 2021-2023 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $77.81 | 2022-2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $68.88 | 2019-2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $63.35 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $51.32 | 2019-2020 | |
| Livanova USA, INC. | $45.77 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Eisai INC. | $43.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $36.26 | 2023-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $26.20 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.78 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $24.69 | 2020 | |
| Tris Pharma INC | $16.93 | 2023 | Dyanavel Xr |
| Lilly USA, LLC | $16.71 | 2025 | Kisunla |
| Shire North American Group INC | $16.39 | 2019 | |
| Alfasigma USA, INC. | $15.19 | 2021 | |
| Acadia Pharmaceuticals INC | $14.82 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harcharan Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.